Business Context and Reporting Period
This Form 8-K reports on the completion of the 2022 Annual Meeting of Stockholders for enVVeno Medical Corporation (NVNO), held on November 30, 2022. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The primary material event was the stockholder vote on two proposals. Of the 9,471,932 shares entitled to vote, 5,450,210 shares were present or represented by proxy.
Proposal 1: Election of Class II Directors
- Mr. Robert A. Berman: Elected with 2,378,488 votes for, 697,978 withheld, and 2,373,744 broker non-votes.
- Mr. Matthew M. Jenusaitis: Elected with 1,869,004 votes for, 1,207,462 withheld, and 2,373,744 broker non-votes.
- Term: Both directors serve a three-year term expiring at the 2025 annual meeting.
Proposal 2: Ratification of Independent Auditor
- Auditor: Marcum LLP was ratified for the fiscal year ending December 31, 2022.
- Votes: 5,445,167 for, 4,108 against, 935 abstaining, and 0 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the current share count and voting power distribution given the significant number of broker non-votes (2,373,744) on director elections.
- Confirm the tenure and background of the newly elected Class II directors, Robert A. Berman and Matthew M. Jenusaitis.
- Review the full 2022 Annual Report (Form 10-K) for financial performance data, as this 8-K contains no financial metrics.
- Check for any subsequent filings regarding the company's status as an emerging growth company and its compliance with related accounting standards.